SPARC entered into a licensing agreement with Biomodifying
Sun Pharma Advanced Research Company (SPARC) has entered into a licensing agreement with Biomodifying to acquire exclusive rights for antibody against unique... Read More
AstraZeneca – Alexion $39 billion deal
Posted on15 Dec 2020
Tagsacquisition in pharma, global pharma deals, largest ever pharma deal, monoclonal antibody, pharma deal, ravulizumab, Soliris, Ultomiris
Comments0
AstraZeneca has agreed to buy US drugmaker Alexion Pharmaceuticals for $39 billion to bolster its positions in immunology and rare diseases. Alexion... Read More
AstraZeneca and Silence Therapeutics co-development siRNA therapeutics
AstraZeneca will collaborate with Silence Therapeutics to discover, develop and commercialise small interfering RNA (siRNA) therapeutics for the treatment of cardiovascular (CV),... Read More
Pfizer’s Upjohn and Mylan merged business entity will be namea as Viatris
The name of the new company to be formed by the merger of Mylan and Upjohn, a division of Pfizer, will be... Read More
S. Korea’s Mediforum acquires local pharma firms C-TRI, i-World Pharm
South Korean bio-pharma company Mediforum Co. has acquired two local pharmaceutical firms C-TRI and i-World, a move that is expected to help... Read More
Alexion acquisition of Achillion: A 1 Billion Pharma Strategic Deal
Posted on21 Oct 2019
TagsAchillion, acquisition in pharma, Alexion Pharmaceuticals, global pharma deals, pharma deal, pharma strategic deal
Comments0
Achillion focuses on the development of oral small-molecule Factor D inhibitors to treat people with rare diseases affecting the ‘complement system’, such... Read More
2018 Pharma Deal: Sanofi’s agreement to buy Bioverati @ $10.9 billion
Posted on18 Dec 2018
TagsBioverati, global pharma deals, global pharma licensing deal, pharma acquisition, pharma deal, Sanofi
Comments0
Sanofi and Bioverativ Inc., a biopharmaceutical company focused on therapies for hemophilia and other rare blood disorders, have entered into a definitive... Read More
2018 Pharma Deal: Novartis’ acquisition of AveXis: $8.1 billion
Posted on18 Dec 2018
TagsAveXis, global pharma deals, global pharma licensing deal, novartis, pharma acquisition, pharma deal
Comments0
Novartis has agreed to acquire the US-based Nasdaq-listed clinical stage gene therapy company for USD 218 per share or a total of... Read More
Pharma R&D Deal Termination: Daiichi Sankyo & GSK’s vaccine JV in Japan
Daiichi Sankyo Company, Limited announced that Daiichi Sankyo and GlaxoSmithKline K.K have agreed to dissolve their joint venture company, Japan Vaccine Co,... Read More
Pharma aaquisition: Aurobindo to acquire dermatology and oral solids businesses from Sandoz Inc. for $900 million
Aurobindo Pharma’s US based subsidiary Aurobindo Pharma USA Inc has entered into a definitive agreement with Sandoz Inc., USA, a Novartis division,... Read More